Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Vanguard Capital Management reported beneficial ownership of 7,104,536 shares of Alnylam Pharmaceuticals common stock, representing 5.35% of the class as of 03/31/2026. The filing shows Vanguard has sole dispositive power over 7,104,536 shares and sole voting power for 1,157,830 shares. The filing is signed by Ashley Grim on 04/29/2026.
Alnylam Pharmaceuticals’ Chief Human Resources Officer Melissa McLaughlin reported routine share sales tied to equity compensation taxes.
The Form 4 shows a total sale of 3,910 shares of common stock on April 2 and 6, 2026, executed automatically under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding on vested restricted stock units. After these transactions, she holds 9,443 shares directly. The filing notes the sales were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on December 16, 2025, indicating they were scheduled in advance rather than opportunistic trades.
Alnylam Pharmaceuticals executive Melissa McLaughlin, Chief Human Resources Officer, reported her equity holdings in the company. She directly holds 13,353 shares of common stock, including restricted stock units that will convert into shares over time.
She also holds a stock option covering 3,567 shares of common stock at an exercise price of $325.07 per share, expiring on March 2, 2036. The option and RSUs vest over multi‑year schedules tied to her continued service.
Alnylam Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on May 20, 2026 at 10:30 a.m. Eastern Time. Holders of record as of March 25, 2026 can participate online and vote.
Stockholders will elect three Class I directors—Stuart Arbuckle, CEO Yvonne L. Greenstreet, M.D., and Elliott Sigal, M.D., Ph.D.—for terms ending in 2029, cast an advisory say‑on‑pay vote on executive compensation, and ratify PricewaterhouseCoopers LLP as independent auditors for 2026.
The proxy highlights Alnylam’s classified board structure, majority voting policy, and a board composed of nine independent and one management director, with a mix of biopharma, financial, governance and scientific expertise. It also details ESG and corporate responsibility initiatives, including patient access programs, climate and data governance work, and a refreshed director compensation mix of cash, stock options and RSUs.
Alnylam Pharmaceuticals Inc: Amendment No. 10 to a Schedule 13G/A filed by The Vanguard Group reports zero shares beneficially owned of Alnylam common stock and 0% ownership as disclosed in the form. The filing includes a statement that Vanguard reorganized certain subsidiaries on January 12, 2026, and those entities will report separately following SEC Release No. 34-39538.
ALNYLAM PHARMACEUTICALS, INC. EVP and Chief R&D officer Pushkal Garg reported open-market sales of 4,713 shares of common stock on March 4–5, 2026, at prices generally in the low-to-mid $320s per share, in multiple transactions.
The filing notes that some shares were automatically sold by the company to cover minimum statutory tax withholding when restricted stock units vested, and that certain transactions were executed under a Rule 10b5-1 trading plan adopted on November 20, 2025. Following these sales, Garg directly held 18,693 common shares, with additional indirect holdings reported through a managed account and a trust, the latter with a disclaimer of beneficial ownership.
Alnylam Pharmaceuticals Chief Executive Officer Yvonne Greenstreet reported automatic tax-related stock sales. On March 4, 2026, she sold a total of 2,933 shares of Alnylam common stock in a series of open-market transactions, at weighted average prices ranging from about $318 to $326 per share.
According to the disclosure, these sales were executed by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding tied to vesting restricted stock units. After these sales, Greenstreet directly owned 95,695 shares, and also held 407 shares indirectly through a managed account related to the company’s 401(k) matching program.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported selling 2,468 shares of common stock on March 4, 2026 in a series of open-market sales. Reported prices for these transactions include $319.03, $320.01, $320.81, $321.82, $323.01, $323.84, $324.88 and $325.67 per share.
According to a footnote, these shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations upon the vesting of restricted stock units. After these sales, Poulton directly owned 62,028 shares and indirectly held 57 shares of ALNY common stock through a managed account.